Apterna is a UK-based, preclinical biotechnology company developing a new generation of precision-delivered RNA therapeutics. Founded by scientists and clinicians from Imperial College London and the City of Hope, we are addressing one of the most important challenges in modern medicine: how to deliver RNA safely and effectively to the right organ, at the right dose, with the right durability.

Our work bridges two areas of profound unmet need. The first is metabolic and liver disease driven by obesity, where liver dysfunction can limit the real-world safety, escalation, and long-term durability of GLP-1 receptor agonist therapy. The second is oncology involving the brain, where effective delivery across the blood-brain barrier remains a central barrier to progress. Using validated, non-viral delivery technologies, Apterna’s goal is to demonstrate that RNA medicines can be both powerful and precise: acting exactly where they are needed, while minimising unwanted systemic exposure.

As a preclinical-stage company, we are preparing for IND and CTA-enabling studies for our lead liver-directed programme and continuing validation of our brain-targeted platform. Every experiment advances our vision of a future where complex diseases can be addressed at their molecular roots through safe, organ-selective RNA therapeutics.